Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early clozapine versus usual second-line antipsychotic treatment after first antipsychotic failure in schizophrenia
ACTRN12625000327482Phase 4Not yet recruiting
- Sponsor
- Lyell McEwin Hospital
- Start
- Apr 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of clozapine in schizophrenia, schizoaffective disorder and schizophreniform disorder, sponsored by Lyell McEwin Hospital. Primary endpoint: Change in symptom severity total score. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
clozapine
03
Conditions
schizophreniaschizoaffective disorderschizophreniform disorder
Beyond the preview
Go deeper on ACTRN12625000327482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000327482.